MDMA for Borderline Personality Disorder
(MDMA in BPD Trial)
Recruiting in Palo Alto (17 mi)
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Yale University
No Placebo Group
Prior Safety Data
Approved in 1 Jurisdiction
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
Research Team
SK
Sarah K Fineberg, MD, PhD
Principal Investigator
Yale University
Eligibility Criteria
This trial is for adults with Borderline Personality Disorder. Specific eligibility criteria are not provided, but typically participants must meet diagnostic criteria for the condition being studied and may need to pass certain health checks.Inclusion Criteria
Willing to remain overnight at the study site after each experimental session if recommended
Able to provide written informed consent according to Yale IRB guidelines
Able to read and write English proficiently
See 11 more
Exclusion Criteria
History of bipolar disorder, schizophrenia, schizoaffective disorder, or currently exhibiting psychotic features
My heart often beats faster than 90 beats per minute.
I have a history of serious medical or neurological illness.
See 10 more
Treatment Details
Interventions
- MDMA (Other)
Trial OverviewThe study is testing the effects of MDMA on social cognition in individuals with Borderline Personality Disorder. Social cognition involves how people process, store, and apply information about others and social situations.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open-Label MDMAExperimental Treatment1 Intervention
Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Trials
1,963
Recruited
3,046,000+
Nancy J. Brown
Yale University
Chief Medical Officer since 2020
MD from Yale School of Medicine
Peter Salovey
Yale University
Chief Executive Officer since 2013
PhD in Psychology from Yale University
Connecticut Mental Health Center
Collaborator
Trials
2
Recruited
160+